In Segment C, individuals will get ABBV-744 and oral navitoclax. In Section D, members will obtain ABBV-744 and ruxolitinib. Individuals will obtain treatment right until disease progression or the participants are unable to tolerate the study drugs. All round, our recent work highlights the potential utilization of ARV-825 in combination https://joshuam776bny0.wonderkingwiki.com/user